<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599128</url>
  </required_header>
  <id_info>
    <org_study_id>1717NRC</org_study_id>
    <nct_id>NCT03599128</nct_id>
  </id_info>
  <brief_title>Effect of Phenolic Acids on the Human Vasculature</brief_title>
  <official_title>Effect of Phenolic Acids on the Human Vasculature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates effects of different doses of phenolic acids on healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been suggested that consumption of food rich in phenolic acids can help to improve
      vascular health, measured by flow mediated dilation (FMD).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2018</start_date>
  <completion_date type="Actual">December 11, 2018</completion_date>
  <primary_completion_date type="Actual">October 4, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy by oral administration of phenolic acid in improving endothelial function</measure>
    <time_frame>6 hours</time_frame>
    <description>Average change from baseline in %FMD at any time point post treatment. Responses will be calculated as the percentage change in brachial artery diameter from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(Area Under Curve) of the concentration/time curve</measure>
    <time_frame>6 hours</time_frame>
    <description>link between endothelial function improvement in healthy subjects and plasma concentration of phenolic acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>6 hours</time_frame>
    <description>link between endothelial function improvement in healthy subjects and plasma concentration of phenolic acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life</measure>
    <time_frame>6 hours</time_frame>
    <description>link between endothelial function improvement in healthy subjects and plasma concentration of phenolic acids</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood concentrations in plasma.</measure>
    <time_frame>6 hours</time_frame>
    <description>Blood concentrations in plasma.</description>
  </other_outcome>
  <other_outcome>
    <measure>To investigate safety of investigational products: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>through study completion, an average of 1 year.</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>43.3 mg hydrolyzed green coffee extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hydrolyzed green coffee extract as interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>86.6 mg hydrolyzed green coffee extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hydrolyzed green coffee extract as interventions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>173 mg hydrolyzed green coffee extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hydrolyzed green coffee extract as interventions</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>43.3 mg hydrolyzed green coffee extract</intervention_name>
    <description>Reconstituted in water and given to subjects</description>
    <arm_group_label>43.3 mg hydrolyzed green coffee extract</arm_group_label>
    <other_name>Phenolic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>86.6 mg hydrolyzed green coffee extract</intervention_name>
    <description>Reconstituted in water and given to subjects</description>
    <arm_group_label>86.6 mg hydrolyzed green coffee extract</arm_group_label>
    <other_name>Phenolic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>173 mg hydrolyzed green coffee extract</intervention_name>
    <description>Reconstituted in water and given to subjects</description>
    <arm_group_label>173 mg hydrolyzed green coffee extract</arm_group_label>
    <other_name>Phenolic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Reconstituted in water and given to subjects</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>maltodextrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or postmenopausal female healthy volunteers aged 45-65 years old

          -  Willing and able to sign written informed consent prior to trial entry

          -  Healthy as determined by the medical history and physical examination

        Exclusion Criteria:

          -  Premenopausal women

          -  Current smokers

          -  Abnormal blood pressure as defined as follow: systolic &lt;90 or &gt;140 mmHg and diastolic
             &lt;60 or &gt;90 mmHg

          -  Regular consumption of cholesterol-lowering medication

          -  Regular consumption of antihypertensive medication

          -  Regular consumption of any vasoactive medication that cannot be discontinued for at
             least 4 half-lives before the FMD assessment

          -  Any food allergies

          -  Any intakes of multivitamin-tablets and other supplemental compounds 10 days before
             the study start and throughout the study

          -  Inability to refrain from coffee/tea and alcohol consumption for 12 h prior to study
             visits

          -  Acute or chronic major psychiatric illness or other major illness that in the opinion
             of the investigator would make the subjects' participation in the study unsafe or
             prevent them from fully complying with the study procedures

          -  Body mass index (BMI) outside 18-32 kg/m2 range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Tan</last_name>
    <role>Study Chair</role>
    <affiliation>Nestlé</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Western Australia</name>
      <address>
        <city>Crawley</city>
        <state>Perth</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

